Fc-y Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer

Geoffrey Liu, Dongsheng Tu, Marcia Lewis, Dangxiao Cheng, Leslie Sullivan, Zhuo Chen, Eric Morgen, John Simes, Timothy Price, Niall Tebbutt, Jeremy Shapiro, Mark Jeffery, J. Daniel Mellor, Thomas Mikeska, Shakeel Virk, Lois Shepherd, Derek Jonker, Christopher O'Callaghan, John Zalcberg, Christos KarapetisAlexander Dobrovic

    Research output: Contribution to journalArticle

    Original languageEnglish
    Pages (from-to)2435-2444
    Number of pages10
    JournalClinical Cancer Research
    Volume22
    Issue number10
    Publication statusPublished - 2016

    Cite this

    Liu, G., Tu, D., Lewis, M., Cheng, D., Sullivan, L., Chen, Z., Morgen, E., Simes, J., Price, T., Tebbutt, N., Shapiro, J., Jeffery, M., Mellor, J. D., Mikeska, T., Virk, S., Shepherd, L., Jonker, D., O'Callaghan, C., Zalcberg, J., ... Dobrovic, A. (2016). Fc-y Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. Clinical Cancer Research, 22(10), 2435-2444.